Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

被引：0
|
作者：
Anette Woehl
Mark Evans
Anthony P Tetlow
Philip McEwan
机构：
[1] Cardiff University,School of Mathematics
[2] University Hospital of Wales,Department of Diabetes, Endocrinology and Metabolism
[3] Cardiff Research Consortium,undefined
来源：
Cardiovascular Diabetology | / 7卷
关键词：
Glycaemic Control; Insulin Glargine; Exenatide; Severe Hypoglycaemia; United Kingdom Prospective Diabetes Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
    Woehl, Anette
    Evans, Mark
    Tetlow, Anthony P.
    McEwan, Philip
    [J]. CARDIOVASCULAR DIABETOLOGY, 2008, 7 (1)
  • [2] Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland
    Braendle, M.
    Erny-Albrecht, K. M.
    Goodall, G.
    Spinas, G. A.
    Streit, P.
    Valentine, W. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (08) : 501 - 515
  • [3] Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies
    Davies, Melanie
    Sinnassamy, Patrick
    Storms, Fred
    Gomis, Ramon
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 (02) : 368 - 375
  • [4] Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (08) : 559 - 569
  • [5] COST-UTILITY OF EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
    Ordonez, J. E.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [6] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [7] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [8] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2018, 38 : 67 - 77
  • [9] Exenatide and insulin glargine are equally effective in patients with suboptimally controlled type 2 diabetes
    Lofthouse M.
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (1): : 7 - 7
  • [10] Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting
    Mittendorf, T.
    Smith-Palmer, J.
    Timlin, L.
    Happich, M.
    Goodall, G.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (11): : 1068 - 1079
12345